Pharmacokinetic profile and incurred sample stability of hydroxychloroquine in Volumetric Absorptive Microsampling (VAMS) using high-performance liquid chromatography-photodiode array
DOI:
https://doi.org/10.46542/pe.2024.246.116123Keywords:
Hydroxychloroquine, Incurred sample stability, PDA, Systemic lupus erythematosus, Volumetric absorptive microsamplingAbstract
Background: Hydroxychloroquine (HCQ) is a quinoline compound derived from chloroquine used to treat SLE. An in vitro stability evaluation was conducted to develop and validate the hydroxychloroquine analysis method. However, an assessment of the incurred sample stability is needed to ensure drug effectiveness, as in vitro evaluation doesn't reflect drug metabolism processes in the body.
Objective: This research aims to obtain a pharmacokinetic profile of hydroxychloroquine using Volumetric Absorptive Microsampling (VAMS) as a safe sampling technique to use during the COVID-19 pandemic and evaluate the incurred sample stability of hydroxychloroquine samples.
Methods: The chromatographic conditions used were column C18 (Waters, XBridge; 250 × 4.6 mm; 5μm); mobile phase acetonitrile-1% diethylamine (65:35); flow rate of 0.8 mL/min; column temperature 45°C; PDA detector analysis wavelength of 332 nm; and chloroquine as internal standard.
Results: The pharmacokinetic profile of hydroxychloroquine in VAMS samples gave results that the Cmax ranged from 322.61-505.32 ng/mL with an average of 425.33 ± 65.90 ng/mL; tmax was 4 hours; mean t1/2 was 23.32 ± 9.65 hours; mean AUC0-72 was 5103.63 ± 1419.66 ng.h/mL; mean AUC0-∞ was 5763.97 ± 2155.26 ng.h/mL, and the AUC ratio was above 80%.
Conclusion: The incurred sample stability of hydroxychloroquine in VAMS met the 2011 EMEA Bioanalytical Guideline requirements up to day 30.
References
De Kesel, P. M. M, Capiau, S., Lambert, W. E., & Stove, C. P. (2014). Current strategies for coping with the hematocrit problem in dried blood spot analysis. Bioanalysis, 6(14). https://doi.org/10.4155/bio.14.151
European Medicines Agency. (2011). Guideline on bioanalytical method validation. European Medicines Agency. Retrieved July 23, 2020 from https://www.ema.europa.eu/en/bioanalytical-method-validation
Harahap, Y., Aisy, S. A. R., Maggadani, B. P. (2021). Development and validation of the quantification method for hydroxychloroquine in Volumetric Absorptive Microsampling (VAMS) using high-performance liquid chromatography-photodiode array. Advances in Pharmacological and Pharmaceutical Sciences, 2021, 3500279. https://doi.org/10.1155/2021/3500279
Harahap, Y., Diptasaadya, R., & Purwanto, D. J. (2020). Volumetric absorptive microsampling as a sampling alternative in clinical trials and therapeutic drug monitoring during the COVID-19 pandemic: A review. Drug Design, Development and Therapy, 14, 5757‒5771. https://doi.org/10.2147/DDDT.S278892
Kip, A. E., Kiers, K. C., Rosing, H., Schellens, J. H. M., Beijnen, J. H., & Dorlo, T. P.. (2017). Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples. Journal of Pharmaceutical and Biomedical Analysis, 135, 160–166. https://doi.org/10.1016/j.jpba.2016.12.012
Kok, M. G. M., & Fillet, M. (2018). Volumetric absorptive microsampling: Current advances and applications. Journal of Pharmaceutical and Biomedical Analysis, 147, 288‒296. https://doi.org/10.1016/j.jpba.2017.07.029
Lowes, S., LeLacheur, R., Shoup, R., … , Watson, A. (2014). Recommendations on incurred sample stability (ISS) by GCC [White paper]. Bioanalysis, 6(18). https://doi.org/10.4155/bio.14.155
Perhimpunan Reumatologi Indonesia. (2019). Rekomendasi perhimpunan reumatologi Indonesia: Diagnosis dan pengelolaan lupus Eretematosus sistemik. Perhimpunan Reumatologi Indonesia. Retrieved June 19, 2021, from https://reumatologi.or.id/wp-content/uploads/2020/10/Diagnosis_dan_pengelolaan_SLE.pdf
Protti, M., Mandrioli, R., & Mercolini, L. (2019). Tutorial: Volumetric absorptive microsampling (VAMS). Analytica Chimica Acta. 1046, 32‒47. https://doi.org/10.1016/j.aca.2018.09.004
